NGM BIOPHARMACEUTICALS INC (NGM) Fundamental Analysis & Valuation

NASDAQ:NGM • US62921N1054

Current stock price

1.54 USD
-0.02 (-1.28%)
At close:
1.55 USD
+0.01 (+0.65%)
After Hours:

This NGM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NGM Profitability Analysis

1.1 Basic Checks

  • In the past year NGM has reported negative net income.
  • In the past year NGM has reported a negative cash flow from operations.
  • NGM had negative earnings in each of the past 5 years.
  • In the past 5 years NGM always reported negative operating cash flow.
NGM Yearly Net Income VS EBIT VS OCF VS FCFNGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of NGM (-84.31%) is worse than 74.87% of its industry peers.
  • NGM's Return On Equity of -95.79% is in line compared to the rest of the industry. NGM outperforms 40.20% of its industry peers.
Industry RankSector Rank
ROA -84.31%
ROE -95.79%
ROIC N/A
ROA(3y)-55.71%
ROA(5y)-41.91%
ROE(3y)-64.77%
ROE(5y)-48.77%
ROIC(3y)N/A
ROIC(5y)N/A
NGM Yearly ROA, ROE, ROICNGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

  • NGM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGM Yearly Profit, Operating, Gross MarginsNGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NGM Health Analysis

2.1 Basic Checks

  • NGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NGM has been increased compared to 1 year ago.
  • NGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NGM Yearly Shares OutstandingNGM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
NGM Yearly Total Debt VS Total AssetsNGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -4.16, we must say that NGM is in the distress zone and has some risk of bankruptcy.
  • NGM has a Altman-Z score of -4.16. This is in the lower half of the industry: NGM underperforms 61.81% of its industry peers.
  • NGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.16
ROIC/WACCN/A
WACC9.2%
NGM Yearly LT Debt VS Equity VS FCFNGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 7.79 indicates that NGM has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 7.79, NGM is in the better half of the industry, outperforming 79.90% of the companies in the same industry.
  • A Quick Ratio of 7.79 indicates that NGM has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 7.79, NGM belongs to the best of the industry, outperforming 80.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.79
Quick Ratio 7.79
NGM Yearly Current Assets VS Current LiabilitesNGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NGM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.10% over the past year.
  • NGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.02%.
  • The Revenue for NGM have been decreasing by -47.30% on average. This is quite bad
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y-47.3%
Sales Q2Q%-99.09%

3.2 Future

  • Based on estimates for the next years, NGM will show a small growth in Earnings Per Share. The EPS will grow by 6.98% on average per year.
  • NGM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 69.25% yearly.
EPS Next Y29.44%
EPS Next 2Y20.23%
EPS Next 3Y11.9%
EPS Next 5Y6.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y94.76%
Revenue Next 5Y69.25%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NGM Yearly Revenue VS EstimatesNGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2028 2029 2030 100M 200M 300M
NGM Yearly EPS VS EstimatesNGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. NGM Valuation Analysis

4.1 Price/Earnings Ratio

  • NGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGM Price Earnings VS Forward Price EarningsNGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGM Per share dataNGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.23%
EPS Next 3Y11.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NGM Dividend Analysis

5.1 Amount

  • No dividends for NGM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NGM Fundamentals: All Metrics, Ratios and Statistics

NGM BIOPHARMACEUTICALS INC

NASDAQ:NGM (4/4/2024, 8:17:51 PM)

After market: 1.55 +0.01 (+0.65%)

1.54

-0.02 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-02
Inst Owners3.6%
Inst Owner Change0%
Ins Owners1.26%
Ins Owner Change0%
Market Cap128.53M
Revenue(TTM)4.42M
Net Income(TTM)-142.38M
Analysts49.09
Price Target1.7 (10.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.62%
Min EPS beat(2)16.9%
Max EPS beat(2)18.33%
EPS beat(4)3
Avg EPS beat(4)8.18%
Min EPS beat(4)-11.04%
Max EPS beat(4)18.33%
EPS beat(8)6
Avg EPS beat(8)6.31%
EPS beat(12)8
Avg EPS beat(12)3.05%
EPS beat(16)9
Avg EPS beat(16)1.01%
Revenue beat(2)0
Avg Revenue beat(2)-73.67%
Min Revenue beat(2)-76.61%
Max Revenue beat(2)-70.73%
Revenue beat(4)0
Avg Revenue beat(4)-67.12%
Min Revenue beat(4)-76.61%
Max Revenue beat(4)-57.45%
Revenue beat(8)3
Avg Revenue beat(8)-14.9%
Revenue beat(12)4
Avg Revenue beat(12)-13.87%
Revenue beat(16)6
Avg Revenue beat(16)-10.32%
PT rev (1m)-60.88%
PT rev (3m)-60.88%
EPS NQ rev (1m)-27.96%
EPS NQ rev (3m)-27.96%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.11
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0.05
BVpS1.78
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -84.31%
ROE -95.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.71%
ROA(5y)-41.91%
ROE(3y)-64.77%
ROE(5y)-48.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.37%
Cap/Sales 28.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.79
Quick Ratio 7.79
Altman-Z -4.16
F-Score3
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)43.33%
Cap/Depr(5y)40.9%
Cap/Sales(3y)11.29%
Cap/Sales(5y)7.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y29.44%
EPS Next 2Y20.23%
EPS Next 3Y11.9%
EPS Next 5Y6.98%
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y-47.3%
Sales Q2Q%-99.09%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y94.76%
Revenue Next 5Y69.25%
EBIT growth 1Y8.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.47%
OCF growth 3YN/A
OCF growth 5YN/A

NGM BIOPHARMACEUTICALS INC / NGM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NGM BIOPHARMACEUTICALS INC (NGM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NGM.


What is the valuation status for NGM stock?

ChartMill assigns a valuation rating of 0 / 10 to NGM BIOPHARMACEUTICALS INC (NGM). This can be considered as Overvalued.


How profitable is NGM BIOPHARMACEUTICALS INC (NGM) stock?

NGM BIOPHARMACEUTICALS INC (NGM) has a profitability rating of 0 / 10.


What is the earnings growth outlook for NGM BIOPHARMACEUTICALS INC?

The Earnings per Share (EPS) of NGM BIOPHARMACEUTICALS INC (NGM) is expected to grow by 29.44% in the next year.